Thomas Schinecker, future Roche CEO

The new CEO at Roche has fol­lowed a fa­mil­iar path in­to the C-suite. But it's his next steps that are cru­cial to his suc­cess

Af­ter Sev­erin Schwan got the nod as the new CEO of Roche, it es­caped no one’s at­ten­tion that he had been steeped in Basel cor­po­rate cul­ture since his pro­fes­sion­al ca­reer be­gan as a trainee in cor­po­rate fi­nance.

His suc­ces­sor — Thomas Schi­neck­er — has been cut out of the ex­act same bolt of cloth.

No soon­er had the Aus­tri­an com­plet­ed his doc­tor­ate in mol­e­c­u­lar bi­ol­o­gy at NYU than he jumped in­to the man­age­ment de­vel­op­ment pro­gram at Roche. And he’s had 19 years of steady ad­vance­ment, lead­ing to his cur­rent gig as head of the fast-grow­ing di­ag­nos­tics di­vi­sion, which any­one at Roche could tell you lies at the heart of its R&D strat­e­gy for ad­vanc­ing per­son­al­ized meds to a first or best-in-class sta­tus.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.